# CJC-1295 reported effects, what people say, and safety cautions > CJC-1295 effects from research-use communities and the clinical literature: what people commonly report, the safety cautions grounded in mechanism and study data, and what the Phase 1 trials actually measured. What research-use communities report alongside what the published literature documents — with safety cautions grounded in mechanism and trial data. ## The short version CJC-1295 is a growth hormone secretagogue — it stimulates the pituitary to release more of the body's own growth hormone rather than replacing it directly. The two controlled human trials from 2006 confirmed that it raises growth hormone two- to ten-fold for six or more days and lifts IGF-1 for nine to eleven days after a single injection, while leaving the natural pulsatile rhythm of GH secretion intact [1][3]. What communities report from research use lines up roughly with those pharmacological effects: better sleep, faster recovery, and slow changes in body composition are the most consistent accounts. Adverse effects center on water retention and related effects of sustained GH elevation. CJC-1295 is not approved for human use anywhere and has never completed Phase 3 clinical trials. WADA prohibits it in sport at all times. ## What people report The following is drawn from research-use community discussions, wellness-clinic write-ups, and consumer side-effect summaries. **These are anecdotal, not clinical evidence.** They are presented because they consistently pattern across sources and align with the pharmacology, not because they are confirmed clinical outcomes. No doses are stated or implied. **Reported benefits:** - *Deeper, more restful sleep* (very commonly reported): Better and deeper sleep is the single most consistent benefit — often the first thing people notice, sometimes within the first week. This fits the known biology: growth hormone is released mainly during deep slow-wave sleep, and GHRH-axis stimulation amplifies that pattern [14]. - *Faster recovery from training* (frequently reported): Many accounts describe recovering more quickly between hard workouts and experiencing less lingering soreness. This is one of the primary reasons fitness communities seek the compound. - *Gradual fat loss, especially around the midsection* (frequently reported): Personal accounts describe slow, progressive fat reduction over several weeks when combined with diet and exercise — most reports note weeks three to six before change is visible. These are personal accounts, not clinical measurements. - *Leaner appearance and better muscle retention* (frequently reported): Users describe looking more defined and maintaining muscle more easily while dieting. The community consistently frames this as subtle and slow rather than dramatic. - *More daytime energy, focus, or clarity* (occasionally reported): Some people report more sustained energy or a clearer head, typically attributed to sleeping better rather than any direct effect. Others notice nothing. **Reported adverse effects:** - *Water retention, bloating, and puffiness* (very commonly reported): Holding extra water is the most commonly reported downside. Communities note it is more pronounced with the long-acting DAC form, because the DAC form keeps GH elevated for days. Most accounts say it eases over time. - *Tingling or numbness in the hands and fingers* (frequently reported): Pins-and-needles or numbness, often compared to mild carpal tunnel, is frequently reported and attributed to fluid retention pressing on wrist nerves. Described as dose-related and reversible. - *Injection-site reactions* (frequently reported): Redness, itching, or mild swelling at the injection site is among the most consistently mentioned local effects. - *Fatigue, drowsiness, or headache* (occasionally reported): Some people report unusual tiredness or mild headaches around the time of a dose. These are inconsistent — others report more energy — and are not universal. - *Higher blood sugar or reduced insulin sensitivity* (occasionally reported): Some users report blood sugar moving up or insulin working less well during extended use, consistent with growth hormone being glucose-sparing. This is anecdotal but mechanistically plausible and noted more often with the long-acting DAC form. ## Safety and cautions The following safety cautions are grounded in mechanism, trial data, or regulatory findings. **Not approved for human use.** CJC-1295 has no approved indication anywhere. It is sold as a research chemical. Published human evidence is limited to early pharmacology studies [1]; there are no large or long-term controlled trials. A 2026 review of unapproved peptide therapies noted this evidence gap directly [21]. **Sustained IGF-1 elevation and theoretical cancer risk.** CJC-1295 keeps IGF-1 elevated for nine to eleven days after a single injection. A large epidemiologic meta-analysis in *The Lancet* linked higher circulating IGF-1 to a modestly increased risk of certain cancers [22]. This is a population-level association, not proof that this compound causes cancer, but the mechanism is real and the long-acting DAC form sustains the exposure. **Fluid retention and nerve-compression.** Growth hormone stimulates renal sodium reabsorption, expanding fluid volume [23]. This is the mechanism behind the water retention, puffiness, and carpal-tunnel-like tingling widely reported by research-use communities. People prone to swelling, elevated blood pressure, or cardiac strain should treat this as a real mechanistic concern. **Blood sugar and insulin sensitivity.** Growth hormone is glucose-sparing. Sustained GH-axis stimulation can reduce insulin sensitivity and raise blood glucose. A clinical study of a GHRH analog documented effects on insulin sensitivity [24]. People with diabetes, prediabetes, or insulin resistance have the most reason for caution. **Immunogenicity flagged by the FDA.** The 2024 FDA Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns as part of the basis for not recommending CJC-1295 for the 503A compounding bulks list [25]. A current *Nature Reviews Endocrinology* review of GHRH analogs reinforces that long-acting albumin-conjugated designs carry this consideration [26]. The Phase 2 trial (NCT00267527) was also discontinued before completion [27]. **DAC and no-DAC forms are routinely confused.** The DAC form stays active for days; the no-DAC form (Modified GRF 1-29) lasts minutes to hours. This distinction matters for safety: the DAC form drives more sustained fluid retention, blood-sugar shifts, and IGF-1 exposure [4]. Knowing which form is under discussion is essential before interpreting any reported effect. **Prohibited in sport at all times.** CJC-1295 is banned by WADA under Section S2 [28]. Detection by LC-MS/MS is confirmed [15]. Any tested athlete who uses it risks a violation. --- An independent digest of peer-reviewed research — not a clinic, not a vendor, not medical advice.